Joseph Mortimer
Associate Director, Translational Biology
At ExEd Joseph leads the translation of intronized therapeutics to demonstrate the functional performance of engineered gene designs. He brings experience in assay development and translational modelling to support therapeutic applications of the platform in relevant biological contexts.
Bio
Joseph previously led discovery biology at Xap Therapeutics, moving the company’s first programme from target identification through in vivo tumour localisation and helping define the essential characteristics of a new cell therapy modality. Earlier in his career at GlaxoSmithKline, he worked across CAR T and AAV programmes, identifying safety-critical off-target interactions, generating preclinical data for IND submissions, and supporting improvements in cell therapy manufacturing and functional performance.
At ExEd Joseph leads the translation of intronized therapeutics to demonstrate the functional performance of engineered gene designs. He brings experience in assay development and translational modelling to support therapeutic applications of the platform in relevant biological contexts.
Bio
Joseph previously led discovery biology at Xap Therapeutics, moving the company’s first programme from target identification through in vivo tumour localisation and helping define the essential characteristics of a new cell therapy modality. Earlier in his career at GlaxoSmithKline, he worked across CAR T and AAV programmes, identifying safety-critical off-target interactions, generating preclinical data for IND submissions, and supporting improvements in cell therapy manufacturing and functional performance.
At ExEd Joseph leads the translation of intronized therapeutics to demonstrate the functional performance of engineered gene designs. He brings experience in assay development and translational modelling to support therapeutic applications of the platform in relevant biological contexts.
Bio
Joseph previously led discovery biology at Xap Therapeutics, moving the company’s first programme from target identification through in vivo tumour localisation and helping define the essential characteristics of a new cell therapy modality. Earlier in his career at GlaxoSmithKline, he worked across CAR T and AAV programmes, identifying safety-critical off-target interactions, generating preclinical data for IND submissions, and supporting improvements in cell therapy manufacturing and functional performance.
→